Development of a Nanoliposomal Formulation of Erlotinib for Lung Cancer and in vitro/In vivo Antitumoral Evaluation [Retraction]
Lists
Only you see this
Abstract
[This retracts the article DOI: 10.2147/DDDT.S146925.].
BibTeX
@inproceedings{zhou2022development,
author = {Xiaofang Zhou and Hui Tao and Kai-hu Shi},
title = {{Development of a Nanoliposomal Formulation of Erlotinib for Lung Cancer and in vitro/In vivo Antitumoral Evaluation [Retraction]}},
booktitle = {Drug},
year = {2022},
doi = {10.2147/dddt.s398024},
}Loading related content...